首页/数据集/Dosing algorithms for dose finding portion of study.

Dosing algorithms for dose finding portion of study.

Figshare2015-12-03 更新2026-04-29 收录

临床试验剂量探索

药物剂量算法

数据链接：

https://figshare.com/articles/dataset/_Dosing_algorithms_for_dose_finding_portion_of_study_/1409700 数据链接链接失效反馈

官方服务：

资源简介：

*Starting dose levelDosing algorithms for dose finding portion of study.

应用场景：

创建时间：

2015-12-03

肿瘤免疫治疗

临床试验剂量探索

This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with sele

NIAID Data Ecosystem120

Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

非小细胞肺癌免疫治疗

临床试验剂量探索

ORR, DCR, and BOR in patients treated with cobolimab 100, 300, or 900 mg plus dostarlimab.

Figshare2025-08-14 更新50

Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

晚期结直肠癌联合化疗

临床试验剂量探索

The purpose of this study is to determine the highest, tolerated dose level and safety of lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the clinical activit

NIAID Data Ecosystem50

Study of XL281 in Adults With Solid Tumors

实体瘤靶向治疗

临床试验剂量探索

The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and ho

NIAID Data Ecosystem70

Toxicity scenarios for the two-agent trial with target probability of toxicity 0.2.

临床试验剂量探索

毒性评估

MTDs are in bold.

Figshare2019-11-11 更新50